Business
Change in Spire Healthcare's directors
Change in Spire Healthcare's directors.
About this update from Spire Healthcare Group Plc
[{"type":"text","content":"\n\nSpire Healthcare Group plc\n \n('Spire Healthcare', 'the Company' or 'the Group')\n \nChange in Spire Healthcare's directors\n \n6 March 2025\n \nSpire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK, today announces that, having completed over 10 years of service, Professor Dame Janet Husband has decided to step down from the Board at the Company's annual general meeting on 14 May 2025 and will not seek re-election by shareholders. The Company is pleased to announce the following Non-Executive Director appointments effective as of today.\n \nNon-Executive Director appointments\n \nSir David Sloman will join as a non-independent Non-Executive Director. Sir David will become a member of the Company's Clinical Governance and Safety Committee on appointment and will replace Dame Janet as chair on 14 May 2025. He will also take on the role of Vice Chair from this date.\n \nSir David has had a long career in healthcare management, predominantly in the NHS. He has held several CEO roles at several NHS trusts, including the Royal Free London NHS Foundation Trust, the Whittington Hospital NHS Trust and NHS Haringey Trust. During December 2021 and August 2023, he was the COO of NHS England, where he was responsible for overseeing all NHS operational delivery, including the response to the COVID-19 pandemic. Sir David is a non-executive director of AXA UK and Ireland, a board member of Health Data Research UK, a fellow of the Royal Society of Medicine, a senior fellow of the Institute for Healthcare Improvement and a trustee of the Royal College of Radiologists. As a result of Sir David's appointment with AXA UK and Ireland, the Company does not consider him to be independent.\n \nJill Anderson will join as an independent Non-Executive Director. Jill will become a member of the Company's Audit and Risk Committee on appointment and will become chair from 14 May 2025. She will also become a member of the Remuneration Committee on appointment. Jill has 30 years' experience in the healthcare sector, including executive responsibility in finance, commercial, research and supply chain functions across large multinational organisations principally with GSK plc. She is a trustee of Amref UK, an NGO focused on healthcare in Africa, and was an associate non-executive dire...